Clinical Research Directory
Browse clinical research sites, groups, and studies.
Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:
Sponsor: Dafne Balemans
Summary
Ten to 15 percent of couples in their reproductive lifetime face fertility problems which is defined by WHO as the absence of pregnancy after minimal 12 months of unprotected sexual intercourse. The three most frequent causes of subfertility are: sperm defects, ovulation disorders and tubal pathology. In order to exclude tubal pathology, tubal patency tests are performed under ultrasound guidance with foam (hysterosalpingo-foam sonography (Hyfosy)) or with contrast/water (hysterosalpingo-contrast sonography (Hycosy)). This trial will investigate whether tubal flushing with an oil-soluble contrast medium (OSCM) can increase the likelihood of a spontaneous conception after tubal patency testing with Hyfosy under ultrasound guidance compared to no additional flushing in a population of infertile women between 18 and 40 years of age with absence of pregnancy after 12 months of unprotected sexual intercourse or who have three cycles of donor insemination without pregnancy or three ovulatory ovulation induction cycles without pregnancy. The use of Lipiodol Ultra Fluide® is off-label in Hyfosy. This multicenter, randomised, open-label, comparative and pragmatic trial compares 2 arms which will be randomised 1:1: * Intervention group: Tubal flush with 5-10mL oil-soluble contrast medium (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy * Control group: No additional intervention after Hyfosy The study comprises a screening period of maximum 8 weeks (w-8 to d1), randomisation (w-8 to d1), a start study visit at which the Hyfosy is performed (d1) and a fertility treatment period of 6 months (d1-w26). If the woman is not pregnant at 6 months after Hyfosy, the follow-up will last till 12 months (w52). If the participant is pregnant at 6 months after Hyfosy, the follow-up will last till maximal 4 months after live birth or miscarriage. The primary endpoint is the occurrence of live birth, with the first day of the last menstrual cycle in which the patient conceives within 6 months after Hyfosy. Secondary endpoints consist of reproductive outcomes, gestational age at delivery, birth weight, neonatal mortality, major congenital anomaly, neonatal outcomes and thyroid function, pregnancy complications, number of complications during or immediately after the intervention, pain score of the Hyfosy and additional flush, thyroid function of the mother, general and disease-specific quality of life.
Official title: Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing: a Randomised, Multicentre, Parallel Group Pragmatic Trial in Infertile Women With at Least One Patent Tube at Hysterosalpingo-foam Sonography
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
736
Start Date
2021-05-25
Completion Date
2027-06-01
Last Updated
2025-11-20
Healthy Volunteers
No
Conditions
Interventions
Lipiodol Ultra Fluide®
Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
Locations (16)
Antwerp University Hospital
Antwerp, Belgium
GZA Sint Augustinus
Antwerp, Belgium
Imelda
Bonheiden, Belgium
AZ Klina
Brasschaat, Belgium
AZ Sint Jan Brugge
Bruges, Belgium
CHIREC
Brussels, Belgium
UCL Saint Luc
Brussels, Belgium
UZ Brussel
Brussels, Belgium
Ziekenhuis Oost Limburg
Genk, Belgium
AZ Sint Lucas
Ghent, Belgium
UZ Gent
Ghent, Belgium
Hôpital Erasme
Lennik, Belgium
UZ Leuven
Leuven, Belgium
CHC Mont Légia
Liège, Belgium
CHR Citadelle
Liège, Belgium
AZ Turnhout
Turnhout, Belgium